<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/CD8980BA-D3E7-4673-80DE-348F6F1CD11C"><gtr:id>CD8980BA-D3E7-4673-80DE-348F6F1CD11C</gtr:id><gtr:name>PC Therapeutics LLP</gtr:name></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/F325BF32-08AE-4621-8057-E5D6613B7308"><gtr:id>F325BF32-08AE-4621-8057-E5D6613B7308</gtr:id><gtr:name>St George's University of London</gtr:name><gtr:department>Basic Medical Sciences</gtr:department><gtr:address><gtr:line1>Cranmer Terrace</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>SW17 0RE</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/F325BF32-08AE-4621-8057-E5D6613B7308"><gtr:id>F325BF32-08AE-4621-8057-E5D6613B7308</gtr:id><gtr:name>St George's University of London</gtr:name><gtr:address><gtr:line1>Cranmer Terrace</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>SW17 0RE</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/CD8980BA-D3E7-4673-80DE-348F6F1CD11C"><gtr:id>CD8980BA-D3E7-4673-80DE-348F6F1CD11C</gtr:id><gtr:name>PC Therapeutics LLP</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/4FDE1DF5-E3DA-4803-A829-E1C9F8BA7F6F"><gtr:id>4FDE1DF5-E3DA-4803-A829-E1C9F8BA7F6F</gtr:id><gtr:firstName>Mark</gtr:firstName><gtr:otherNames>Rutherford</gtr:otherNames><gtr:surname>Sanderson</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/466CC49E-5B81-4CEB-8CF2-5F105D12C677"><gtr:id>466CC49E-5B81-4CEB-8CF2-5F105D12C677</gtr:id><gtr:firstName>Larry Mark</gtr:firstName><gtr:surname>Fisher</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=BB%2FH00405X%2F1"><gtr:id>4B25D317-15C5-4B82-A820-24D3DC0BFF7F</gtr:id><gtr:title>Mechanistic and structural analysis of topo IV and gyrase and their targeting by antibacterial quinolones</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>BB/H00405X/1</gtr:grantReference><gtr:abstractText>Topo IV and gyrase are enzymes that untangle bacterial chromosomes and are important targets of anti-infective drugs. Both enzymes make a DNA break (known as a 'gate') in one DNA molecule and pass a second DNA helix through the gate. Quinolone drugs kill bacteria by stabilizing the enzyme-opened gate. This project aims to understand how topo IV and gyrase mediate gate opening and closure, and how drugs interfere with these fundamental processes. The study builds on insights gained from our recent X-ray crystal structure that revealed how quinolones act at the topo IV-DNA gate. This structure provides a number of intriguing mechanistic hypotheses to be tested and paves the way for the design and evaluation of new inhibitors with novel modes of action that should minimize the emergence of drug resistance.</gtr:abstractText><gtr:technicalSummary>Topo IV and DNA gyrase regulate DNA supercoiling and chromosome segregation and are important targets of antibacterial quinolones used against Streptococcus pneumoniae and other Gram-positive organisms. Both enzymes act by passing a DNA duplex through a transient double-stranded break in a 'gate' or G-duplex involving formation of a transient covalent enzyme-DNA intermediate known as the 'cleavage complex'. In a very important advance, we recently solved the crystal structure of cleavage complexes formed by the topo IV ParC breakage-reunion- and ParE metal binding (TOPRIM) domains in complex with a G-DNA gate stabilised by moxifloxacin and clinafloxacin, two antipneumococcal fluoroquinolones. The structure suggests how the DNA G-gate may operate in tandem with N- and C- protein gates to facilitate DNA transport, and moreover provides a wealth of drug-enzyme-DNA information to guide drug design. We aim to test a number of hypotheses relating to how ParE interacts with ParC, DNA or ATP to coordinate gate recognition and opening. In addition, a combination of biochemical, structural and chemical approaches will be used to investigate novel topo IV inhibitors engineered to have greater potency, that target topo IV and gyrase equally (dual action to minimise development of resistance) or act irreversibly (to reduce resistance). Completion of the work will provide new insights on the reaction cycle of topo IV and gyrase and their interactions with novel antibacterial drugs.</gtr:technicalSummary><gtr:fund><gtr:end>2012-08-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/2512EF1C-401B-4222-9869-A770D4C5FAC7"><gtr:id>2512EF1C-401B-4222-9869-A770D4C5FAC7</gtr:id><gtr:name>BBSRC</gtr:name></gtr:funder><gtr:start>2009-09-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>620906</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>PC Therapeutics LLP</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>PTC Therapeutics drug development</gtr:description><gtr:id>D065D690-FE64-4135-A983-EBDCE6A84F6C</gtr:id><gtr:impact>Outcomes confidential as yet.</gtr:impact><gtr:outcomeId>54649dd5c1e765.98552727-1</gtr:outcomeId><gtr:partnerContribution>Provision of novel antibacterial agents, expertise in microbiology of bacterial pathogens</gtr:partnerContribution><gtr:piContribution>Bichemical and structural expertise and determination of enzyme-drug-DNA crystal structures</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs><gtr:impactSummaryOutput><gtr:description>The eight crystal structures of topo IV-DNA-drug complexes that we deposited in the Protein Data Bank are valuable open resource to the pharmaceutical industry in guiding new drug development. Indeed, the PLoS One publication describing some of these structures has been well cited. Moreover, the work has led to a number of collaborative initiatives with pharmaceutical companies to understand the structural and mechanistic aspects of new drugs they are developing.</gtr:description><gtr:firstYearOfImpact>2010</gtr:firstYearOfImpact><gtr:id>92812C7F-3FCA-4393-8BFC-F55920536629</gtr:id><gtr:impactTypes><gtr:impactType>Societal,Economic</gtr:impactType></gtr:impactTypes><gtr:outcomeId>546478772254d7.89237826</gtr:outcomeId><gtr:sector>Education,Healthcare,Pharmaceuticals and Medical Biotechnology</gtr:sector></gtr:impactSummaryOutput></gtr:impactSummaryOutputs><gtr:intellectualPropertyOutputs/><gtr:keyFindingsOutput><gtr:description>1. Solved the first high-resolution X-ray structures of an antimicrobial quinazolinedione with its DNA-topoisomerase II target (S. pneumoniae topo IV)(PDB entries 3LTN, 3RAF).
Quinazolinediones are of considerable interest as antibacterial candidates as they circumvent resistance to quinolones. Comparison with X-ray structures determined here for quinolone-DNA complexes of topo IV with levofloxacin (3K9F, 3RAE,) and clinafloxacin (3RAD) explains the mode of drug action and lack of cross-resistance between the drug classes.
2. First crystal structures of drug-free DNA-topo IV complexes in precleaved (3KSB) and cleaved (3KSA) states, the first for putative reaction intermediates in the topoisomerase II reaction cycle, revealing the role of magnesium ions and DNA conformational changes at the bent DNA gate.
Structures in 1 and 2 published in Laponogov et al PLoS ONE (2010).
3. Solved the first full-length 3-gate structure of a bacterial type II topoisomerase-DNA complex which provides new insights on topoisomerase II action.</gtr:description><gtr:exploitationPathways>Access to our structures of topo IV-DNA complexes with antibacterial quinolones and diones greatly benefit the pharmaceutical industry in their efforts to understand current antibacterial drugs and to develop new agents with novel modes of action that circumvent quinolone resistance. 

The structural and biochemical work is also of use to enzymologists, biologists and chemists in understanding topoisomerase action.</gtr:exploitationPathways><gtr:id>B72F1FB0-1839-487E-A4E8-74781EDD96C5</gtr:id><gtr:outcomeId>5464743961b928.34615420</gtr:outcomeId><gtr:sectors><gtr:sector>Education,Healthcare,Pharmaceuticals and Medical Biotechnology</gtr:sector></gtr:sectors></gtr:keyFindingsOutput><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>ED28AAAD-008C-4204-9B3C-1941A4FF399F</gtr:id><gtr:title>Functional determinants of gate-DNA selection and cleavage by bacterial type II topoisomerases.</gtr:title><gtr:parentPublicationTitle>Nucleic acids research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/551bda1a8156f71fe66df1f07a3b1f0d"><gtr:id>551bda1a8156f71fe66df1f07a3b1f0d</gtr:id><gtr:otherNames>Arnoldi E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0305-1048</gtr:issn><gtr:outcomeId>5463b2609521e4.58746972</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>22D0A973-16AA-4D53-80F7-A114DB02EAD9</gtr:id><gtr:title>Exploring the active site of the Streptococcus pneumoniae topoisomerase IV-DNA cleavage complex with novel 7,8-bridged fluoroquinolones.</gtr:title><gtr:parentPublicationTitle>Open biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/757758d1cad053304eaebed51bf8f2d8"><gtr:id>757758d1cad053304eaebed51bf8f2d8</gtr:id><gtr:otherNames>Laponogov I</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>2046-2441</gtr:issn><gtr:outcomeId>585d3ae8220fa5.54826579</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>70F637C6-020C-4D7C-A6C9-687E24C213B6</gtr:id><gtr:title>Structure and function of eukaryotic DNA binding proteins in DNA repair</gtr:title><gtr:parentPublicationTitle>International Review of Biophysical Chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9f0d0d7c309f187089ca2191d7655c53"><gtr:id>9f0d0d7c309f187089ca2191d7655c53</gtr:id><gtr:otherNames>Kind S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:outcomeId>54647349b750d6.82668264</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>070944CE-BD0F-4642-8231-A05F6068591E</gtr:id><gtr:title>Structure of a quinolone-stabilized cleavage complex of topoisomerase IV from Klebsiella pneumoniae and comparison with a related Streptococcus pneumoniae complex.</gtr:title><gtr:parentPublicationTitle>Acta crystallographica. Section D, Structural biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/91d441db8d7792cda42802c10d1aed80"><gtr:id>91d441db8d7792cda42802c10d1aed80</gtr:id><gtr:otherNames>Veselkov DA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>2059-7983</gtr:issn><gtr:outcomeId>585d70a66faf66.45716086</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>32766B08-CDE9-42E3-A5C6-C63C4185321D</gtr:id><gtr:title>Structural basis of gate-DNA breakage and resealing by type II topoisomerases.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/757758d1cad053304eaebed51bf8f2d8"><gtr:id>757758d1cad053304eaebed51bf8f2d8</gtr:id><gtr:otherNames>Laponogov I</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>54647020e21564.01260433</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">BB/H00405X/1</gtr:identifier></gtr:identifiers><gtr:healthCategories/><gtr:researchActivities/><gtr:researchSubjects/><gtr:researchTopics><gtr:researchTopic><gtr:id>D05BC2E0-0345-4A3F-8C3F-775BC42A0819</gtr:id><gtr:text>Unclassified</gtr:text></gtr:researchTopic></gtr:researchTopics><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>